Filtered By:
Cancer: Colorectal Cancer

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 51727 results found since Jan 2013.

A long-term retrospective observational study at a medium-sized medical oncology service in Switzerland: comparison of overall survival with a national cohort and adherence to treatment guidelines
CONCLUSIONS: The statistically comparable local 1- and 5-year overall survival of the analysed malignancies, with adjustment for stage for the 5-year overall survival for breast cancer, is in line with the national benchmark. Adherence to treatment guidelines is high.PMID:37459836 | DOI:10.57187/smw.2023.40091
Source: Swiss Medical Weekly - July 17, 2023 Category: General Medicine Authors: Mirjam Gross-Erne Lukas Zimmerli Stefano Bassetti Qiyu Li Anita Feller Walter Mingrone Source Type: research

Assessment of reproducibility of cancer survival risk predictions across medical centers
Conclusions: This study illustrates an analytical approach to assessing reproducibility of predictive models and signatures. Based on the analyses of the two cancer datasets, we conclude that the models with clinical variables appear to perform reasonable well with high degree of consistency and transferability. There should have more investigations on the reproducibility of prediction models including gene expression data across studies.
Source: BMC Medical Research Methodology - Latest articles - February 20, 2013 Category: Research Authors: Hung-Chia ChenJames Chen Source Type: research

Owlstone Medical launches 1,400-patient study for colon cancer ‘ breathalyzer ’
Owlstone Medical said today it is launching a 1,400-patient clinical trial of its breath-based colorectal cancer diagnostic technology. The Intercept trial aims to explore the accuracy of the U.K.-based company’s ‘breathalyzer’ test in detecting colorectal cancer at an early stage. Owlstone’s breathalyzer uses field asymmetric ion mobility spectrometry to detect volatile organic compound metabolites in a person’s breath or bodily fluids. Volatile organic compound biomarkers can be used to non-invasively diagnose disease at a very early stage, according to the company, which could get a patient into tr...
Source: Mass Device - February 7, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Diagnostics Oncology Owlstone Medical Source Type: news

Creo Medical wins expanded CE mark for Speedboat RS2 electrosurgical device
Creo Medical said today it won expanded CE mark approval for its Speedboat RS2 electrosurgical device, now cleared for the use of microwave energy as well as radiofrequency. The U.K.-based company said that in a 30-patient clinical study, the Speedboat RS2 successfully demonstrated safety and efficacy in applying microwave energy to coagulate bleeds in the colon. Creo Medical touted the device as the 1st to use microwave energy combined with radiofrequency. “Our vision is to enable physicians to move the point of treatment from the operating theatre under general anaesthetic to a procedure under sedation in the endo...
Source: Mass Device - March 24, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Regulatory/Compliance Surgical Vascular Creo Medical Source Type: news

Estimating Associations Between Medical Home Adoption, Utilization, and Quality: A Comparison of Evaluation Approaches
Conclusions: The findings of medical home evaluations are sensitive to methodological choices. Meta-analyses, narrative reviews, and other syntheses of medical home studies should consider subdividing their findings by analytic approach.
Source: Medical Care - December 12, 2017 Category: Health Management Tags: Original Articles Source Type: research

Treatment patterns and direct medical costs of metastatic colorectal cancer patients: A retrospective study of electronic medical records from urban China.
Conclusions: Before 2017, mCRC patients in China did not receive the maximum benefits of precision medicine breakthroughs. Reduced treatment cycles and increased costs per cycle from first- to third-line suggested poor healthcare resource utilization. With earlier initiation and more treatment cycles, targeted biologics may better demonstrate their effectiveness among Chinese patients. Our findings reflected the urgent need to increase drug accessibility in China before 2017 and underscore that including innovative biologics into Chinese health insurance plans can reduce patients' economic burden and improve the management...
Source: Journal of Medical Economics - January 19, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Two medical pioneers aim to trial a cancer-killing virus. I aim to help out | Alexander Masters
A pair of researchers in Sweden may have a revolutionary cancer treatment on their hands. But a separate revolution will be needed to get it to marketJust north of Stockholm, among the creaking Swedish ice-forests, three revolutions for 2013 are taking place.Revolution One: Two researchers at the University of Uppsala have engineered a virus that will attack cancer. Cheap, precise, with only mild, flu-like side-effects, this plucky little microbe sounds too good to be true. Yet in peer-reviewed articles in top journals, Professor Magnus Essand and Dr Justyna Leja have repeatedly showed that Ad5[CgA-E1A-miR122]PTD views hea...
Source: Guardian Unlimited Science - January 4, 2013 Category: Science Authors: Alexander Masters Tags: Comment The Guardian Crowdsourcing Health Medical research Society Technology Kickstarter Features Cancer Internet Science Comment is free Source Type: news

Risk of colon perforation during colonoscopy at Baylor University Medical Center.
Abstract Colonoscopy is an important procedure in preventing colon cancer. The risk of colonic perforation during colonoscopy at the Baylor University Medical Center (BUMC) Gastrointestinal Laboratory was chosen as a surrogate marker for the safety of colonoscopy. A recent 2-year experience at BUMC was examined and compared with reports in the medical literature. The results are presented here along with a discussion of problems inherent with different health care systems and their ability to accurately track complications. It was concluded that colonoscopy at BUMC is as safe as that reported by comparable health ...
Source: Baylor University Medical Center Proceedings - January 1, 2015 Category: Universities & Medical Training Authors: Polter DE Tags: Proc (Bayl Univ Med Cent) Source Type: research

Uptake Medical touts 1st-in-human use of Intervapor lung cancer device
Uptake Medical said it’s InterVapor targeted vapor therapy system has been used in the 1st-ever regional lung cancer tumor ablation procedure. The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the company said. The patient treated with the system was diagnosed with colorectal cancer that metastasized to the lung. The procedure was performed by Dr. Arschang Valipour at Vienna’s Otto-Wagner-Spital Hospital, Tustin, Calif.-based Uptake said. “InterVapor is the only therapy with the promise of quick, simple, complete bronchoscopic ab...
Source: Mass Device - October 12, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Respiratory Uptake Medical Source Type: news

Uptake Medical launches InterVapor lung device
Uptake Medical said today it launched a registry trial of its InterVapor system to investigate long-term clinical results in severe emphysema patients. The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the company said. “Until InterVapor, severe emphysema was typically treated either by requiring patients to undergo highly invasive open surgical lobectomy, or applying foreign material into their lungs. InterVapor offers a less-invasive, bronchoscopic approach that allows clinicians to limit treatment only to the discrete portions of a patien...
Source: Mass Device - January 14, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology Respiratory Uptake Medical Source Type: news

Owlstone Medical raises $11.6m for disease breathalyzer device
Owlstone Medical said today that it raised $11.6 million to help fund its disease breathalyzer device. The round was led by existing investors and follows an original investment of $7 million that spun the Cambridge, England-based company out in June last year. The funds will be used to commercially launch Owlstone’s breath biomaker R&D services, as the company opens a new high volume clinical facility and continues its ongoing clinical trials in lung and colon cancer diagnostics. Owlstone’s breathalyzer uses field asymmetric ion mobility spectrometry to detect volatile organic compound metabolites in a per...
Source: Mass Device - January 6, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diagnostics Funding Roundup Wall Street Beat Owlstone Medical Source Type: news